⌘K
Loading ticker…
Ironwood Pharmaceuticals, Inc. - Class A · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) has a 3-month relative strength percentile of 81 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 89. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.0%, relative volume 3.44×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 81, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
IRWD is in a stage 2 uptrend, week 1. Currently in a 107-day base; basing ADR 6.9% (broad 9.7%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 6.9% / 23.9%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
IRWD is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $15M notional. Top 3 carry $43M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $15M |
| XBIState Street SPDR S&P Biotech ETF | 0.19% | $14M |
| IWMiShares Russell 2000 ETF | 0.02% | $14M |
| VXFVanguard Extended Market ETF | 0.01% | $6M |
| IWOiShares Russell 2000 Growth ETF | 0.03% | $4M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $672K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IRWD Jan avg: 3.74% median: 8.51% win: 50% σ: 40.13% n: 4 2022-04-12 → 2026-05-29 | IRWD Feb avg: -24.24% median: -30.63% win: 0% σ: 14.79% n: 4 2022-04-12 → 2026-05-29 | IRWD Mar avg: -5.09% median: -7.14% win: 25% σ: 5.21% n: 4 2022-04-12 → 2026-05-29 | IRWD Apr avg: -6.67% median: -2.20% win: 20% σ: 19.69% n: 5 2022-04-12 → 2026-05-29 | IRWD May avg: -13.89% median: -13.46% win: 20% σ: 15.00% n: 5 2022-04-12 → 2026-05-29 | IRWD Jun avg: 5.83% median: 2.90% win: 75% σ: 9.58% n: 4 2022-04-12 → 2026-05-29 (current) | IRWD Jul avg: 3.70% median: 4.49% win: 75% σ: 3.09% n: 4 2022-04-12 → 2026-05-29 | IRWD Aug avg: 5.05% median: -13.34% win: 25% σ: 45.93% n: 4 2022-04-12 → 2026-05-29 | IRWD Sep avg: -3.40% median: -2.24% win: 25% σ: 11.58% n: 4 2022-04-12 → 2026-05-29 | IRWD Oct avg: 10.30% median: 0.74% win: 50% σ: 24.76% n: 4 2022-04-12 → 2026-05-29 | IRWD Nov avg: 23.12% median: 10.53% win: 75% σ: 40.72% n: 4 2022-04-12 → 2026-05-29 | IRWD Dec avg: 10.00% median: 8.93% win: 75% σ: 13.28% n: 4 2022-04-12 → 2026-05-29 |